These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 34982297)
1. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Rizzone MG; Mancini F; Artusi CA; Balestrino R; Bonvegna S; Fabbri M; Imbalzano G; Montanaro E; Romagnolo A; Zibetti M; Lopiano L Neurol Sci; 2022 May; 43(5):3187-3193. PubMed ID: 34982297 [TBL] [Abstract][Full Text] [Related]
2. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease. Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059 [TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients. Cattaneo C; Jost WH; Bonizzoni E J Parkinsons Dis; 2020; 10(1):89-97. PubMed ID: 31594253 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease. Ostrem JL; Ziman N; Galifianakis NB; Starr PA; Luciano MS; Katz M; Racine CA; Martin AJ; Markun LC; Larson PS J Neurosurg; 2016 Apr; 124(4):908-16. PubMed ID: 26495947 [TBL] [Abstract][Full Text] [Related]
5. Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Castrioto A; Lozano AM; Poon YY; Lang AE; Fallis M; Moro E Arch Neurol; 2011 Dec; 68(12):1550-6. PubMed ID: 21825213 [TBL] [Abstract][Full Text] [Related]
6. SW2-year outcomes of subthalamic deep brain stimulation for idiopathic Parkinson's disease. Nunta-Aree S; Sitthinamsuwan B; Boonyapisit K; Pisarnpong A J Med Assoc Thai; 2010 May; 93(5):529-40. PubMed ID: 20524438 [TBL] [Abstract][Full Text] [Related]
8. Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study. Nishikawa N; Hatano T; Nishioka K; Ueno SI; Saiki S; Nakamura R; Yoritaka A; Ogawa T; Shimo Y; Sako W; Shimura H; Furukawa Y; Kamei T; Ishida T; Hattori N; J Neurol Sci; 2024 Jun; 461():123051. PubMed ID: 38788287 [TBL] [Abstract][Full Text] [Related]
9. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE. Cattaneo C; Sardina M; Bonizzoni E J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632 [TBL] [Abstract][Full Text] [Related]
10. Overall Efficacy and Safety of Safinamide in Parkinson's Disease: A Systematic Review and a Meta-analysis. Giossi R; Carrara F; Mazzari M; Lo Re F; Senatore M; Schicchi A; Corrù F; Fittipaldo VA; Pani A; Tramacere I; Elia AE; Scaglione F Clin Drug Investig; 2021 Apr; 41(4):321-339. PubMed ID: 33674954 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis comparing deep brain stimulation of the globus pallidus and subthalamic nucleus to treat advanced Parkinson disease. Liu Y; Li W; Tan C; Liu X; Wang X; Gui Y; Qin L; Deng F; Hu C; Chen L J Neurosurg; 2014 Sep; 121(3):709-18. PubMed ID: 24905564 [TBL] [Abstract][Full Text] [Related]
14. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease. Mueller K; Jech R; Růžička F; Holiga Š; Ballarini T; Bezdicek O; Möller HE; Vymazal J; Růžička E; Schroeter ML; Urgošík D Neuroimage Clin; 2018; 19():1025-1035. PubMed ID: 30035027 [TBL] [Abstract][Full Text] [Related]
15. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt M; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R; Mov Disord; 2014 Feb; 29(2):229-37. PubMed ID: 24323641 [TBL] [Abstract][Full Text] [Related]
16. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R; Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402 [TBL] [Abstract][Full Text] [Related]
17. Real life evaluation of safinamide effectiveness in Parkinson's disease. Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484 [TBL] [Abstract][Full Text] [Related]
18. A comparison of indirect and direct targeted STN DBS in the treatment of Parkinson's disease-surgical method and clinical outcome over 15-year timespan. Lahtinen MJ; Haapaniemi TH; Kauppinen MT; Salokorpi N; Heikkinen ER; Katisko JP Acta Neurochir (Wien); 2020 May; 162(5):1067-1076. PubMed ID: 32103343 [TBL] [Abstract][Full Text] [Related]
19. [Effects of bilateral deep brain stimulation in the subthalamic nucleus using two methods of target structure verification]. Goubareva NN; Fedorova NV; Bril' EV; Tomskiy AA; Gamaleya AA; Poddubskaya AA; Shabalov VA; Omarova SM Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):24-30. PubMed ID: 29265083 [TBL] [Abstract][Full Text] [Related]
20. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. Schapira AH; Fox SH; Hauser RA; Jankovic J; Jost WH; Kenney C; Kulisevsky J; Pahwa R; Poewe W; Anand R JAMA Neurol; 2017 Feb; 74(2):216-224. PubMed ID: 27942720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]